{"product_id":"apoquel-16-mg-comprimate-masticabile-x-100-tb","title":"Apoquel 16 mg comprimate masticabile X 100 TB","description":"\u003cp\u003e\u003cspan\u003e\u003cb\u003eDENUMIREA PRODUSULUI MEDICINAL VETERINAR\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAPOQUEL 16 mg, comprimate filmate pentru câini\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOclacitinib\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e \u003c\/span\u003e\u003cspan\u003e\u003cb\u003eDECLARAREA SUBSTANŢELOR ACTIVE ŞI A ALTOR INGREDIENTE\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFiecare comprimat filmat conţine 3,6 mg oclacitinib, 5,4 mg oclacitinib sau 16 mg oclacitinib, sub formă de maleat de oclacitinib.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eComprimate filmate albe spre alburii, de formă alungită, cu o linie crestată pe ambele părţi şi marcate cu literele „AQ” şi „S”, „M” sau „L” pe ambele părţi.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eLiterele „S”, „M” şi „L” se referă la diferitele concentraţii ale comprimatelor\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\n\u003cspan\u003e\u003c\/span\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cspan\u003e\u003c\/span\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cspan\u003e\u003c\/span\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003eComprimatele pot fi divizate în părţi egale.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cb\u003eINDICAŢIE\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTratamentul pruritului asociat cu dermatita alergică la câini. Tratamentul manifestărilor clinice ale dermatitei atopice la câini.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cb\u003eCONTRAINDICAŢII\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNu folosiţi în caz de hipersensibilitate la oclacitinib sau la oricare din excipienţi.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNu folosiţi la câini cu vârstă mai mică de 12 luni sau cu mai puţin de 3 kg greutate corporală.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNu folosiţi la câini cu semne de supresie imună, cum ar fi hiperadrenocorticism sau cu semne de neoplazie malignă progresivă, întrucât substanţa activă nu a fost evaluată în aceste cazuri.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cb\u003eREACŢII ADVERSE\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCele mai frecvente reacţii adverse urmărite până la ziua 16 a studiilor de pe teren sunt enumerate în tabelul următor, comparate cu substanţa martor:\u003c\/span\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e\n\u003cp\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd colspan=\"2\"\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003eReacţii adverse observate în studiul dermatitei atopice până în ziua a 16-a\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd colspan=\"2\"\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003eReacţii adverse observate în studiul pruritului până în ziua a 7-a\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003eAPOQUEL (n=152)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003eSubstanţă martor (n=147)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003eAPOQUEL (n=216)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003eSubstanţă martor (n=220)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003eDiaree\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e4.6%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e3.4%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e2.3%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e0.9%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003eVomă\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e3.9%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e4.1%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e2.3%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e1.8%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003eLipsa sau pierderea apetitului (Anorexie)\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e2,.6%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e0%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e1.4%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e0%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003eNoi umflături cutanate sau subcutanate\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e2.6%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e2.7%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e1.0%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e0%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003eSlăbiciune (Letargie)\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e2.0%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e1.4%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e1.8%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e1.4%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003eSete excesivă (Polidipsie)\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e0.7%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e1.4%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e1.4%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e0%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDupă ziua 16, semne clinice anormale, adiţionale semnelor clinice enumărate mai sus, observate la peste 1% din câinii cărora li se administrează oclacitinib, includ piodermie, umflături dermice nespecifice, otită, histiocitom, cistită, infecţii cu levuri ale pielii, pododermatită, lipom, limfadenopatie, ameţeală\/ greaţă, apetit crescut şi agresivitate.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTratamentul a indicat că schimbările patologiei clinice au fost restricţionate la o creştere a mediei colesterolului din ser şi o scădere a numarului mediu leucocitar, cu toate acestea, toate valorile medii au rămas în limita referinţelor de laborator. Scăderea numarului mediu leucocitar observat la câinii trataţi cu oclacitinib nu a fost progresiv şi a afectat numarul tuturor celulelor albe sangvine (numarul neutrofilelor, eozinofilelor şi monocitelor), cu excepţia numărului limfocitelor. Niciuna din aceste schimbări ale patologiei clinice nu a părut semnificativă clinic.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e \u003c\/span\u003e\u003cspan\u003eIntr-un studiu de laborator, la un număr de câini, s-a evindenţiat dezvoltarea de papiloame. Frecvenţa reacţiilor adverse a fost definită folosind următoarea convenţie: \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDacă observaţi reacţii grave sau alte efecte care nu sunt menţionate în acest prospect, vă rugăm informaţi medicul veterinar. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cb\u003eSPECII ŢINTĂ\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCâini.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cb\u003ePOSOLOGIE PENTRU FIECARE SPECIE, CALE (CĂI) DE ADMINISTRARE ŞI MOD DE ADMINISTRARE\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePentru administrare orală.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cb\u003eDozaj şi schemă de tratament:\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDoza iniţială recomandată de comprimate APOQUEL ce trebuie administrată la câine este pentru a atinge 0,4 mg până la 0,6 mg oclacitinib\/ kg greutate corporală, administrată oral, de 2 ori pe zi pentru cel mult 14 zile.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePentru terapia de întreţinere (după cele 14 zile iniţiale de tratament), aceeaşi doză (0,4 mg până la 0,6 mg oclacitinib \/ kg greutate corporală) trebuie administrată ulterior o dată pe zi. Necesitatea menţinerii terapiei pe termen lung trebuie bazată pe evaluarea individuală risc-beneficiu efectuată de medicul veterinar.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAceste comprimate pot fi administrate cu sau fară hrană.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e \u003c\/span\u003e\u003cspan\u003eConsultaţi tabelul de dozaj de mai jos pentru numărul de comprimate necesare atingerii dozei recomandate. Comprimatele se pot diviza de-a lungul liniei crestate.\u003c\/span\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e\n\u003cp\u003e\u003cspan\u003e\u003cb\u003e\u003ci\u003eGreutatea corporală (kg) a câinelui\u003c\/i\u003e\u003c\/b\u003e\u003cb\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd colspan=\"3\"\u003e\n\u003cp\u003e\u003cspan\u003e\u003cb\u003e\u003ci\u003eConcentrația și numărul de comprimate de administrat:\u003c\/i\u003e\u003c\/b\u003e\u003cb\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003cb\u003eAPOQUEL \u003c\/b\u003e\u003c\/span\u003e\u003cspan\u003e\u003cb\u003e3,6 mg\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003cb\u003eAPOQUEL \u003c\/b\u003e\u003c\/span\u003e\u003cspan\u003e\u003cb\u003e5.4 mg\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003cb\u003eAPOQUEL\u003c\/b\u003e\u003cb\u003e 16 mg\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003e3.0–4.4\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e½\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003e4.5–5.9\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e½\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003e6.0–8.9\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003e9.0–13.4\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003e13.5–19.9\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e½\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003e20.0–26.9\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e2\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003e27.0–39.9\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003e40.0–54.9\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e½\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e\u003ci\u003e55.0–80.0\u003c\/i\u003e\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e–\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cspan\u003e2\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cb\u003eRECOMANDĂRI PRIVIND ADMINISTRAREA CORECTĂ\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCâinii trebuie observaţi cu atenţie după administrare pentru a ne asigura că fiecare comprimat este înghiţit.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cb\u003eTIMP DE AŞTEPTARE\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNu se aplică.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e \u003c\/span\u003e\u003cspan\u003e\u003cb\u003ePRECAUŢII SPECIALE PENTRU DEPOZITARE\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eA nu se lăsa la vederea şi îndemâna copiilor.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eA nu se păstra la temperatură mai mare de 25 °C.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOrice jumătate de comprimat rămasă trebuie pusă fie înapoi în folia deschisă şi depozitată în ambalajul original de carton fie în flaconul HDPE (pentru cel mult 3 zile).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eA nu se utiliza acest produs medicinal veterinar după data expirării marcată pe etichetă pe blister sau flacon după EXP.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cb\u003eATENŢIONĂRI SPECIALE\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cu\u003ePrecauţii speciale pentru utilizare la animale:\u003c\/u\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOclacitinib modulează sistemul imun şi poate mări susceptibilitatea la infecţii şi să exarcebeze condiţiile neoplazice. Câinii cărora li se administrează comprimatele de APOQUEL trebuie, prin urmare, monitorizaţi în privinţa dezvoltării infecţiilor şi a neoplaziei.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCând se tratează pruritul asociat dermatitei alergice cu oclacitinib, investigaţi şi trataţi orice cauze latente (de exemplu, dermatita alergică la înţepătura de purici, dermatita de contact, hipersensibilitatea alimentară).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDe asemenea, în caz de dermatită alergică sau dermatită atopică, este recomandat a se investiga şi trata factorii complicatori, cum ar fi infecţiile\/ infestaţiile bacteriene, fungice sau parazitare (de exemplu: purici sau râie).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eConsiderând potențialul efect asupra anumitor parametri clinicopatologici se recomandă monitorizarea formulei leucocitare complete şi biochimia serului, la câinii care primesc tratament pe termen de lungă durată.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e \u003c\/span\u003e\u003cspan\u003e\u003cu\u003ePrecauţii speciale care trebuie luate de persoana care administrează produsul medicinal veterinar la animale:\u003c\/u\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSpălaţi mâinile după administrare.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eÎn caz de ingestie accidentală, solicitaţi imediat sfatul medicului şi prezentaţi prospectul produsului sau eticheta medicului.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e \u003c\/span\u003e\u003cspan\u003e\u003cu\u003eUtilizarea în perioada gestaţiei sau lactaţiei:\u003c\/u\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSiguranţa produsului medicinal veterinar nu a fost stabilită pe perioada de gestaţie şi lactaţie sau la masculi de reproducţie, prin urmare nu se recomandă folosirea în timpul gestaţiei, lactaţiei sau la câinii destinaţi reproducţiei.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e \u003c\/span\u003e\u003cspan\u003e\u003cu\u003eInteracţiuni cu alte produse medicinale sau alte forme de interacţiune:\u003c\/u\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNicio interacţiune medicamentoasă nu a fost observată în studiile de teren acolo unde APOQUEL a fost administrat concomitent cu alte produse medicinale veterinare cum ar fi, medicamente împotriva endo- şi ecto paraziţilor, antimicrobiene şi medicamente antiinflamatorii.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eA fost studiat impactul administrării oclacitinib asupra vaccinării cu vaccinuri vii modificate, parvovirusul canin (CPV), virusul jigodiei (CDV) și parainfluenţei canine (IPC) și asupra vaccinarilor cu vaccin antirabic inactivat (RV), la puii de 16 săptămâni. Un răspuns imun adecvat (serologie) la vaccinarea contra CDV și CPV a fost atins atunci când puii au primit oclacitinib în doză de 1,8 mg \/ kg greutate corporală de două ori pe zi, timp de 84 de zile. Cu toate acestea, rezultatele acestui studiu au indicat o reducere a răspunsului serologic la vaccinarea contra IPC și RV la pui tratați cu oclacitinib, comparativ cu lotul martor netratat. Relevanța clinică a acestor efecte la animale vaccinate în timp ce se administrează oclacitinib (în conformitate cu regimul de dozare recomandat) este neclară.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cu\u003eSupradozare (simptome, proceduri de urgenţă, antidoturi):\u003c\/u\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eComprimate de oclacitinib au fost administrate câinilor din rasa Beagle, sănătoşi în vârstă de 1 an, de două ori pe zi timp de 6 săptămâni, urmate de o administrare pe zi timp de 20 săptămâni, la 0,6 mg \/ kg greutate corporală, 1,8 mg \/ kg greutate corporală și 3,0 mg \/ kg greutate corporală pentru un total de 26 săptămâni. \u003c\/span\u003e\u003c\/p\u003e","brand":"Farmacia Zoo","offers":[{"title":"Default Title","offer_id":57271281484102,"sku":null,"price":2290.0,"currency_code":"RON","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/6121\/8118\/files\/apoquel-16-mg-comprimate-masticabile-x-100-tb_809016.webp?v=1788604590","url":"https:\/\/checkout.farmaciazoo.ro\/products\/apoquel-16-mg-comprimate-masticabile-x-100-tb","provider":"Farmacia Zoo","version":"1.0","type":"link"}